Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

EPICOR Asia-China Extension. Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02305680

Acronym

EPICOR

Enrollment

2334

Registered

2014-12-03

Start date

2014-12-17

Completion date

2017-04-05

Last updated

2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Brief summary

This study is to describe the long-term antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome in China.

Detailed description

This study is to describe the long-term (3 to 5 years after the acute coronary syndrome index event) antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome (i.e. ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, Unstable Angina) in China.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Written informed consent has been provided. 2. Contact Order Form has been provided 3. Aged 18 years or older. 4. Enrolled in EPICOR Asia study and completed the 2 year follow-up.

Exclusion criteria

1. Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances, alcohol or drug abuse). 2. Already included in the EPICOR Asia-China Extension observational study. 3. Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy. 4. Current participation in an interventional clinical trial. 5. Patients receiving ticagrelor beyond 12 months and other off label use.

Design outcomes

Primary

Measure	Time frame
Long-term antithrombotic management patterns in a real-life setting by assessing the medication and treatment prescribed by physicians	From 2 years after the acute coronary syndrome index event, assessed up to 5 years

Secondary

Measure	Time frame
Clinical outcomes by record the number and type of cardiovascular and non-cardiovascular events	From 2 years after the acute coronary syndrome index event, assessed up to 5 years
Health care resource consumption and related costs by assessing the detail hospitalization and outpatient cost.	From 2 years after the acute coronary syndrome index event, assessed up to 5 years
Quality of life by assessing EQ-5D questionnaire.	2 years,2.5years,3years,3.5years,4years,4.5years,5years after the acute coronary syndrome index event

Countries

China

Outcome results